{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chen S"],"funding":["Research Fund of the Center for Community Health Care, China Hospital Development Institute, Shanghai Jiao Tong University","Hospital-level Research Project of Shanghai Tongren Hospital","Changning District Science and Technology Commission","Changning District Health Commission"],"pagination":["39624"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12612232"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(1)"],"pubmed_abstract":["Astragaloside IV (AS-IV), an essential active ingredient isolated from Astragalus membranaceus, has exhibited notable antifibrotic properties in diverse disease models. However, its exact role and underlying molecular mechanisms in idiopathic pulmonary fibrosis (IPF) remain insufficiently defined. In this study, we employed an integrative approach combining transcriptomic profiling, network pharmacology, and molecular docking techniques to investigate the critical targets and signaling pathways modulated by AS-IV in the context of IPF. Differentially expressed genes obtained from lung tissue datasets of IPF patients were cross-referenced with AS-IV-associated targets to identify overlapping candidates with potential therapeutic relevance. Gene enrichment analyses revealed that the PI3K-AKT"],"journal":["Scientific reports"],"pubmed_title":["Integrative analysis of the therapeutic mechanisms of Astragaloside IV in idiopathic pulmonary fibrosis via network pharmacology and molecular validation."],"pmcid":["PMC12612232"],"funding_grant_id":["20234Y006","2024SQYL01","TRYJ2021JC01","CNKW2024Y06"],"pubmed_authors":["Yan J","Zhang J","Ma Y","Chen S","Su Y","Yu Y"],"additional_accession":[]},"is_claimable":false,"name":"Integrative analysis of the therapeutic mechanisms of Astragaloside IV in idiopathic pulmonary fibrosis via network pharmacology and molecular validation.","description":"Astragaloside IV (AS-IV), an essential active ingredient isolated from Astragalus membranaceus, has exhibited notable antifibrotic properties in diverse disease models. However, its exact role and underlying molecular mechanisms in idiopathic pulmonary fibrosis (IPF) remain insufficiently defined. In this study, we employed an integrative approach combining transcriptomic profiling, network pharmacology, and molecular docking techniques to investigate the critical targets and signaling pathways modulated by AS-IV in the context of IPF. Differentially expressed genes obtained from lung tissue datasets of IPF patients were cross-referenced with AS-IV-associated targets to identify overlapping candidates with potential therapeutic relevance. Gene enrichment analyses revealed that the PI3K-AKT","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-06-05T12:35:48.206Z","creation":"2026-05-16T03:12:58.286Z"},"accession":"S-EPMC12612232","cross_references":{"pubmed":["41224967"],"doi":["10.1038/s41598-025-23354-8"]}}